{"success":true,"data":{"pressRelease":{"id":"16748","rtpr_id":"nACSCK8SNa","ticker":"AQST","exchange":"NASDAQ","all_tickers":["AQST"],"title":"AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Aquestive Therapeutics, Inc. to Contact the Firm Today!","author":"ACCESSWIRE","published_at":"2026-05-01T11:00:04.025Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized\ninvestor-rights law firm, announces that a class action lawsuit has been filed\nagainst Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain of its\nofficers.\n(https://app.accessnewswire.com/imagelibrary/94aacdad-2f4b-434d-a5ac-de8f3ffd9ff6/image.png)\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aquestive Therapeutics\nsecurities between June 16, 2025 and January 8, 2026, both dates inclusive\n(the \"Class Period\"). Such investors are encouraged to join this case by\nvisiting the firm's site: bgandg.com/AQST.\n(https://bgandg.com/AQST/?utm_source=PRESS_RELEASE_PLACEHOLDER&utm_medium=pressrelease&utm_campaign=AQST)\n\nAquestive Therapeutics Case Details\n\nThe Complaint alleges that, throughout the relevant period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n1.\nthe timeline for approval and launch of Aquestive's New Drug Application\n(\"NDA\") for Anaphylm (dibutepinephrine) sublingual film was materially\noverstated;\n2.\nDefendants' statements expressing confidence in the NDA submission and their\nrepeated assertions that Anaphylm would receive approval by the Prescription\nDrug User Fee Act (\"PDUFA\") date of January 31, 2026 lacked a reasonable\nbasis;\n3.\nthe NDA faced significant risks related to human factors associated with the\nuse of the sublingual film, including packaging, administration, use, and\nlabeling; and\n4.\nDefendants concealed or minimized the material impact of these human‑factors\nissues on the likelihood and timing of regulatory approval.\n\nWhat's Next for Aquestive Therapeutics Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/AQST.\n(https://bgandg.com/AQST/?utm_source=PRESS_RELEASE_PLACEHOLDER&utm_medium=pressrelease&utm_campaign=AQST)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911\n(tel:+9175900911). If you suffered a loss in Aquestive Therapeutics you have\nuntil May 4, 2026, to request that the Court appoint you as lead plaintiff.\nYour ability to share in any recovery doesn't require that you serve as lead\nplaintiff.\n\nNo Cost to Aquestive Therapeutics Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aquestive Therapeutics Securities\nClass Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aqst-investor-alert-bronstein-gewirtz-and-grossman-llc-reminds-i-1144763)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSCK8SNa","title":"AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Aquestive Therapeutics, Inc. to Contact the Firm Today!","author":"ACCESSWIRE","ticker":"AQST","created":"2026-05-01T11:00:04.025Z","tickers":["AQST"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized\ninvestor-rights law firm, announces that a class action lawsuit has been filed\nagainst Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain of its\nofficers.\n(https://app.accessnewswire.com/imagelibrary/94aacdad-2f4b-434d-a5ac-de8f3ffd9ff6/image.png)\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aquestive Therapeutics\nsecurities between June 16, 2025 and January 8, 2026, both dates inclusive\n(the \"Class Period\"). Such investors are encouraged to join this case by\nvisiting the firm's site: bgandg.com/AQST.\n(https://bgandg.com/AQST/?utm_source=PRESS_RELEASE_PLACEHOLDER&utm_medium=pressrelease&utm_campaign=AQST)\n\nAquestive Therapeutics Case Details\n\nThe Complaint alleges that, throughout the relevant period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n1.\nthe timeline for approval and launch of Aquestive's New Drug Application\n(\"NDA\") for Anaphylm (dibutepinephrine) sublingual film was materially\noverstated;\n2.\nDefendants' statements expressing confidence in the NDA submission and their\nrepeated assertions that Anaphylm would receive approval by the Prescription\nDrug User Fee Act (\"PDUFA\") date of January 31, 2026 lacked a reasonable\nbasis;\n3.\nthe NDA faced significant risks related to human factors associated with the\nuse of the sublingual film, including packaging, administration, use, and\nlabeling; and\n4.\nDefendants concealed or minimized the material impact of these human‑factors\nissues on the likelihood and timing of regulatory approval.\n\nWhat's Next for Aquestive Therapeutics Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/AQST.\n(https://bgandg.com/AQST/?utm_source=PRESS_RELEASE_PLACEHOLDER&utm_medium=pressrelease&utm_campaign=AQST)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911\n(tel:+9175900911). If you suffered a loss in Aquestive Therapeutics you have\nuntil May 4, 2026, to request that the Court appoint you as lead plaintiff.\nYour ability to share in any recovery doesn't require that you serve as lead\nplaintiff.\n\nNo Cost to Aquestive Therapeutics Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aquestive Therapeutics Securities\nClass Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aqst-investor-alert-bronstein-gewirtz-and-grossman-llc-reminds-i-1144763)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T11:00:04.087618004Z","server_sent_at_ms":1777633204087},"received_at":"2026-05-01T11:00:04.140Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aqst-investor-alert-bronstein-gewirtz-and-grossman-llc-reminds-i-1144763"},"analysis":null,"durationMs":null,"modelName":null}}